Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration

Retina

Volumn 32, Issue 1, 2012, Pages 4-9

  Orlin, Anton ^a   Hadley, Dexter ^a,b   Chang, Woohyok ^c   Ho, Allen C ^d,e   Brown, Gary ^d,e   Kaiser, Richard S ^d,e   Regillo, Carl D ^d,e   Godshalk, Ashlee N ^e   Lier, Audun ^b   Kaderli, Brian ^b   Stambolian, Dwight ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Yeungnam University College of Medicine   (South Korea)

^d Mid Atlantic Retina   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

age related macular degeneration; genetics; pharmacogenetic response

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ALLELE; ARMS2 GENE; CFH GENE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HTRA1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT FACTOR H; DRUG ADMINISTRATION SCHEDULE; HUMANS; MACULAR DEGENERATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84855170104     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822a2c7c     Document Type: Review

References (28)

1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624. (Pubitemid 37392370)
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485. (Pubitemid 38456282)
3. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-851. (Pubitemid 39573742)
4. Heiba IM, Elston RC, Klein BE, Klein R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 1994;11:51-67. (Pubitemid 24089911)
5. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol 1997;123: 199-206. (Pubitemid 27066775)
6. Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005;123:321-327. (Pubitemid 41007575)
7. Edwards AO, Ritter R III, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424. (Pubitemid 40530082)
8. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232. (Pubitemid 40696361)
9. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421. (Pubitemid 40530081)
10. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389. (Pubitemid 40530070)
11. Souied EH, Leveziel N, Richard F, et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 2005; 11:1135-1140. (Pubitemid 43040543)
12. Zareparsi S, Branham KE, Li M, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005;77:149-153. (Pubitemid 40848046)
13. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314:989-992. (Pubitemid 44749943)
14. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407. (Pubitemid 41192646)
15. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227-3236. (Pubitemid 41631297)
16. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008;40:892-896. (Pubitemid 351913654)
17. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314:992-993. (Pubitemid 44749944)
18. Klein BE, Knudtson MD, Lee KE, et al. Supplements and age-related eye conditions: the Beaver Dam Eye Study. Ophthalmology 2008;115:1203-1208. (Pubitemid 351885399)
19. Feng X, Xiao J, Longville B, et al. Complement factor H Y402H and C-reactive protein polymorphism and photody-namic therapy response in age-related macular degeneration. Ophthalmology 2009;116:1908-1912 e1.
20. Brantley MA Jr, Edelstein SL, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond) 2009;23:626-631.
21. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372 e5.
22. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizu-mab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-390. (Pubitemid 44197628)
23. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114: 2168-2173. (Pubitemid 350181136)
24. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Oph-thalmol 2009;93:610-613.
25. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 2005;123:1570-1574. (Pubitemid 41626694)
26. Hadley D, Orlin A, Brown G, et al. Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci 2010;51:2191-2196.
27. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2010.
28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575. (Pubitemid 47330214)